At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
CBL-514drug
Likely dose
CBL-514 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers
In Brief
A Phase 2 clinical trial evaluating CBL-514 for Subcutaneous Fat. Completed, enrolled 10 participants across 1 site.
Detailed Summary
This Phase 2 study will be an open-label and single course study to assess the safety, tolerability, PK and metabolite profile of CBL-514.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubcutaneous Fat
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedFeb 2022
Enrollment StartFeb 2022
Primary CompletionJun 2022
TodayJul 2026
First PostedFeb 10, 2022
Enrollment StartFeb 11, 2022
Primary CompletionJun 9, 2022
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 4.4 years ago
Interventions
CBL-514drug
CBL-514 800 mg (unit dose: 2.0 mg/cm\^2)